首页 > 用药指导 > 文章详情

Baricitinib(艾乐明)巴瑞替尼的作用功效与副作用

发布时间:2026-01-25 08:13:00 阅读:1632 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

巴瑞替尼片

巴瑞替尼片 生产厂家:孟加拉伊思达(Incepta)制药有限公司 功能主治:JAK1/2抑制剂,用于多种炎症性疾病和自身免疫性疾病 用法用量:用法用量  1、类风湿性关节炎  OLUMIANT的推荐剂量为每日1次口服2mg,餐前餐后都可。  OLUMIANT可以单独使用,也可以与甲氨蝶呤或其他非生物dmard联合使用。  2、COVID-19(新冠病毒)  成人OLUMIANT的推荐剂量为每日一次口服4mg,餐前餐后都可,持续14天或直到出院,以先发生者为准。  3、斑秃  OLUMIANT的推荐剂量是2mg,每天一次口服,餐前餐后都可。  如果对治疗的反应不充分,增加到每天一次4mg。  对于几乎完全或完全的头皮脱发,睫毛或眉毛有或没有大量脱发的患者,考虑每天一次4mg治疗,伴餐前餐后都可。  一旦患者对4mg的治疗产生了充分的反应,将剂量减少到2mg,每天一次。  对于无法吞下整片药片的患者,可以考虑另一种给药方式:  1、口服分散  2、胃造口管(G管)  3、鼻胃管(NG管)或口胃管(OG管)
查看详情

Baricitinib(艾乐明)巴瑞替尼的作用功效与副作用,艾乐明(Baricitinib)常见副作用有:1、严重感染,如肺炎、带状疱疹和尿路感染;2、死亡率,50岁以上及有心血管疾病的患者有更高的全因死亡率;3、恶性肿瘤和淋巴增生性疾病;4、重大心血管不良事件;5、血栓形成;6、会出现过敏反应;7、胃肠道穿孔;8、可能会对胎儿造成损害。

Baricitinib (trade name Olumiant) is a medication that has shown efficacy in the treatment of various inflammatory conditions, including rheumatoid arthritis, COVID-19, and alopecia areata. It belongs to a class of drugs called Janus kinase (JAK) inhibitors, which work by suppressing the activity of certain enzymes involved in the immune response. However, like any medication, Baricitinib can have both beneficial effects and potential side effects. In this article, we will explore the uses, benefits, and potential side effects of Baricitinib.

1. Baricitinib in the Treatment of Rheumatoid Arthritis:

Rheumatoid arthritis is a chronic autoimmune disorder characterized by joint inflammation, pain, and stiffness. Baricitinib has been approved for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded well to other disease-modifying antirheumatic drugs (DMARDs). It helps reduce inflammation and inhibit joint damage, thereby improving symptoms and physical function in patients with this condition.

2. Baricitinib in the Treatment of COVID-19:

During the COVID-19 pandemic, several medications were investigated for their potential to treat the disease caused by the SARS-CoV-2 virus. Baricitinib has shown promise as a treatment option for COVID-19, particularly in hospitalized patients requiring supplemental oxygen or mechanical ventilation. It has been found to reduce the risk of disease progression and improve clinical outcomes in certain patient populations. However, it should be noted that Baricitinib is not a substitute for COVID-19 vaccines or other preventive measures.

3. Baricitinib in the Treatment of Alopecia Areata:

Alopecia areata is an autoimmune condition that causes hair loss, usually in patches, and can progress to complete baldness. Baricitinib has been investigated as a potential treatment for alopecia areata due to its immunomodulatory effects. Preliminary studies have shown promising results, with some patients experiencing hair regrowth after treatment with Baricitinib. However, further research is needed to determine its long-term efficacy and safety for this specific indication.

Common Side Effects of Baricitinib:

While Baricitinib can be effective in treating various conditions, it is important to be aware of its potential side effects. Common side effects include upper respiratory tract infections, headache, nausea, and changes in blood test results (such as elevated cholesterol or liver enzymes). More serious side effects, though rare, may include blood clots, severe infections, malignancies, and allergic reactions. It is essential to discuss any concerns or potential side effects with a healthcare professional.

Conclusion:

Baricitinib, marketed as Olumiant, has shown therapeutic benefits in the treatment of rheumatoid arthritis, COVID-19, and alopecia areata. As a JAK inhibitor, it helps reduce inflammation and modulate the immune response. However, like all medications, it is associated with potential side effects, and its use should be monitored by healthcare professionals. Patients considering or currently taking Baricitinib should consult with their healthcare provider to weigh the potential benefits against the possible risks and to discuss the most appropriate treatment plan for their individual needs.